



## BioCryst to Present at Upcoming Investor Conferences

February 22, 2023

RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](https://www.biocryst.com) (Nasdaq: BCRX) today announced that the company will present at the Cowen 43<sup>rd</sup> Annual Health Care Conference in Boston, MA on Wednesday, March 8<sup>th</sup> at 12:50 p.m. ET and the Barclays 2023 Global Healthcare Conference in Miami, FL on Tuesday, March 14<sup>th</sup> at 9:30 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst's website at <http://www.biocryst.com>.

### About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO<sup>®</sup> (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB<sup>®</sup> (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company's website at [www.biocryst.com](http://www.biocryst.com).

BCRXW

### **Investor Contact:**

John Bluth  
+1 919 859 7910  
[jbluth@biocryst.com](mailto:jbluth@biocryst.com)

### **Media Contact:**

Catherine Collier Kyroulis  
+1 917 886 5586  
[ckyroulis@biocryst.com](mailto:ckyroulis@biocryst.com)